Article info
PDFOriginal research
MiR-21, EGFR and PTEN in non-small cell lung cancer: an in situ hybridisation and immunohistochemistry study
- Correspondence to Dr Nadia Prisant, Pathology Department, Tel HaShomer Hospital, Tel Hashomer 52621, Israel; nprisant{at}gmail.com
Citation
MiR-21, EGFR and PTEN in non-small cell lung cancer: an in situ hybridisation and immunohistochemistry study
Publication history
- Received December 29, 2019
- Revised January 20, 2020
- Accepted January 23, 2020
- First published February 14, 2020.
Online issue publication
December 21, 2020
Article Versions
- Previous version (18 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.